<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">The HBV-reporter cell line, HepG2.2.15 is one of the established systems for preliminary screening of anti-HBV drugs 
 <italic>in vitro</italic>. The 
 <italic>in silico</italic> molecular docking tool enables to assess the binding ability of a ligand to protein active-site as well as to compare the binding modes of different ligands to the active site-pocket (
 <xref rid="b0155" ref-type="bibr">Leach, 2001</xref>). Therefore, in this study, we evaluated the novel anti-HBV activity as well as delineated mechanism of action of selected plant-derived compounds of different classes, using cell culture and molecular docking methods.
</p>
